Our Mission

History

Our Leadership

• Our Team
• Our Board

Corporate Social Responsibility

Transparency Disclosure

BPS-804 (SETRUSUMAB)

MPH-966 (ALVELESTAT)

BCT-197 (ACUMAPIMOD)

BGS-649 (LEFLUTROZOLE)

OMP-305B83 (NAVICIXIZUMAB)

OMP-313M32 (ETIGILIMAB)

Our Approach

Partnering Contact

Current Partnerships

Results, Reports and Presentations

NASDAQ

• Share Price Chart
• SEC Filings
• Whistleblower Services

US Tax

AIM

• AIM Rule 26
• Share Price Chart
• Regulatory News
• Latest Trades
• Detailed Share Price

Register for Email Alerts

Corporate Governance

• Transparency Disclosure
• The QCA 10 Principles
• Board Structure and Responsibilities
• Relationships with Stakeholders and Shareholders
• Board Committees
• Corporate Social Responsibility

Shareholder Information

• Shareholder Analysis
• Analyst Coverage
• Registrar Services
• Investor Contacts and Advisers
• FAQ
• Warning to Shareholders

Events and Conferences

Press Releases

Transparency Disclosure

Our Business Model

Our Strategy